{"entity":{"id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","aka":[],"tldr":"A phase 2 trial of temozolomide and olaparib in triple-negative breast cancer, run by AHS Cancer Control Alberta, not yet recruiting.","summary":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) is a phase 2, randomised interventional study registered as NCT05128734 by AHS Cancer Control Alberta, with a registry enrolment figure of 40 participants, started 2026-04-01 and due to reach its primary completion in 2028-04-01. Interventions recorded: Temozolomide; Olaparib. Conditions listed: Breast Cancer Triple Negative. Triple-negative eligibility wording from the registry: \"* Female or male patients with triple negative breast cancer confirmed by pathology of the primary tumour or metastatic biopsy sample\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05128734","url":"https://clinicaltrials.gov/study/NCT05128734"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["temozolomide","olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05128734","phase":"2","setting":"A Randomized Phase II Study of Temozolomide Monotherapy or in Combination With Olaparib in Patients With METHYLATED 06-Methylguanine-DNA Methyltransferase (MGMT) Pre-Treated Triple Negative Breast Cancer (TNBC)","sponsor":"AHS Cancer Control Alberta","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05128734/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}